trading halt, page-5

yak, the announcement was released by Abbot on 31 December.
So the announcement was already public knowledge for those who did their research

ABT ABT
ABBOTT LABORATORIES NYSE


Back to Headlines | Previous Story

Abbott Laboratories Receives U.S. FDA Approval Earlier Than Anticipated For HUMIRA(TM) (adalimumab) for the Treatment of Rheumatoid Arthritis (RA)

ABBOTT PARK, Ill., Dec 31, 2002 (Canada NewsWire via COMTEX) -- Abbott Laboratories received U.S. Food and Drug Administration (FDA) approval to market HUMIRA(TM) (adalimumab), previously known as D2E7. HUMIRA is the first human monoclonal antibody approved for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active rheumatoid arthritis (RA) who have had insufficient response to one or more traditional disease modifying antirheumatic drugs (DMARDs).

"We're pleased to receive the U.S. approval of HUMIRA earlier than anticipated," said Miles D. White, chairman and chief executive officer, Abbott Laboratories. "The U.S. approval of HUMIRA is not only a milestone for Abbott, more importantly it is an example of the positive impact pharmaceutical innovation can have for people living with chronic and debilitating conditions like RA."


So the announcement was already public knowledge for those who did their research